褪黑素与人类心血管疾病

Melatonin and Human Cardiovascular Disease.

作者信息

Pandi-Perumal Seithikurippu R, BaHammam Ahmed S, Ojike Nwakile I, Akinseye Oluwaseun A, Kendzerska Tetyana, Buttoo Kenneth, Dhandapany Perundurai S, Brown Gregory M, Cardinali Daniel P

机构信息

1 Department of Medicine, College of Medicine, The University Sleep Disorders Center, King Saud University, Riyadh, Saudi Arabia.

2 Division of Health and Behavior, Department of Population Health, New York University Medical Center, Center for Healthful Behavior Change, New York, NY, USA.

出版信息

J Cardiovasc Pharmacol Ther. 2017 Mar;22(2):122-132. doi: 10.1177/1074248416660622. Epub 2016 Jul 27.

DOI:10.1177/1074248416660622

PMID:27450357

Abstract

The possible therapeutic role of melatonin in the pathophysiology of coronary artery disorder (CAD) is increasingly being recognized. In humans, exogenous melatonin has been shown to decrease nocturnal hypertension, improve systolic and diastolic blood pressure, reduce the pulsatility index in the internal carotid artery, decrease platelet aggregation, and reduce serum catecholamine levels. Low circulating levels of melatonin are reported in individuals with CAD, arterial hypertension, and congestive heart failure. This review assesses current literature on the cardiovascular effects of melatonin in humans. It can be concluded that melatonin deserves to be considered in clinical trials evaluating novel therapeutic interventions for cardiovascular disorders.

摘要

褪黑素在冠状动脉疾病（CAD）病理生理学中可能的治疗作用正日益得到认可。在人类中，外源性褪黑素已被证明可降低夜间高血压，改善收缩压和舒张压，降低颈内动脉搏动指数，减少血小板聚集，并降低血清儿茶酚胺水平。据报道，CAD、动脉高血压和充血性心力衰竭患者的循环褪黑素水平较低。本综述评估了目前关于褪黑素对人类心血管影响的文献。可以得出结论，在评估心血管疾病新型治疗干预措施的临床试验中，褪黑素值得考虑。